These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma. Pavia D Respirology; 1997; 2 Suppl 1():S5-10. PubMed ID: 9400688 [TBL] [Abstract][Full Text] [Related]
8. [Progress of research on pressurized metered dose inhalers]. Zhou X Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):213-5. PubMed ID: 23856147 [No Abstract] [Full Text] [Related]
9. Developments in inhaled combination therapies: patent activity 2013-2014. Norman P Expert Opin Ther Pat; 2015; 25(11):1239-45. PubMed ID: 26135360 [TBL] [Abstract][Full Text] [Related]
10. [Fixed-dose combination of proven active ingredients in new inhaler]. Koczorek M Med Monatsschr Pharm; 2014 Sep; 37(9):341-2. PubMed ID: 25282752 [No Abstract] [Full Text] [Related]
11. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Tamura G; Ohta K Respir Med; 2007 Sep; 101(9):1895-902. PubMed ID: 17587559 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma. Bjermer L; Rosenborg J; Bengtsson T; Lötvall J Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810 [TBL] [Abstract][Full Text] [Related]
13. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. Tamm M; Richards DH; Beghé B; Fabbri L Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165 [TBL] [Abstract][Full Text] [Related]
15. Importance of inhaler devices in the management of airway disease. Virchow JC; Crompton GK; Dal Negro R; Pedersen S; Magnan A; Seidenberg J; Barnes PJ Respir Med; 2008 Jan; 102(1):10-9. PubMed ID: 17923402 [TBL] [Abstract][Full Text] [Related]
16. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD]. Henriet AC; Marchand-Adam S; Mankikian J; Diot P Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393 [TBL] [Abstract][Full Text] [Related]
18. Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma. Buhl R; Farmer SG Proc Am Thorac Soc; 2004; 1(2):136-42. PubMed ID: 16113426 [TBL] [Abstract][Full Text] [Related]
19. Changes in inhaler devices for asthma and COPD. Capriotti T Medsurg Nurs; 2005 Jun; 14(3):185-94. PubMed ID: 16035636 [No Abstract] [Full Text] [Related]
20. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. Adi H; Young PM; Traini D J Pharm Pharmacol; 2012 Sep; 64(9):1245-53. PubMed ID: 22881437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]